Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04943848
Title rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ann & Robert H Lurie Children's Hospital of Chicago
Indications

brain stem glioma

diffuse midline glioma, H3 K27M-mutant

Therapies

rHSC-DIPGVax

Balstilimab + rHSC-DIPGVax

Balstilimab + rHSC-DIPGVax + Zalifrelimab

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.